Cargando…

Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR(®) trial

BACKGROUND: The aim of this study was to evaluate whether Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification could predict mortality risk factors and whether baseline treatment intensity would relate to mortality within each group, using data from TIOSPIR(®), the largest ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dusser, Daniel, Wise, Robert A, Dahl, Ronald, Anzueto, Antonio, Carter, Kerstine, Fowler, Andy, Calverley, Peter M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725639/ https://www.ncbi.nlm.nih.gov/pubmed/26855568 http://dx.doi.org/10.2147/COPD.S97924

Ejemplares similares

Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR(®) trial
por: Wise, Robert A, et al.
Publicado: (2018)

The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes
por: Anzueto, Antonio, et al.
Publicado: (2015)

Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial
por: Dahl, Ronald, et al.
Publicado: (2015)

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study
por: Calverley, Peter MA, et al.
Publicado: (2017)

Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial
por: Wise, Robert, et al.
Publicado: (2015)

The Tiotropium Safety and Performance in Respimat® Trial (TIOSPIR®), a large scale, randomized, controlled, parallel-group trial-design and rationale
por: Wise, Robert A, et al.
Publicado: (2013)

Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
por: Putcha, Nirupama, et al.
Publicado: (2022)

Tiotropium safety in ‘real‐world’ populations: Response to Schmiedl, et al. in the British Journal of Clinical Pharmacology
por: Wise, Robert, et al.
Publicado: (2016)

Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD
por: Calverley, Peter MA, et al.
Publicado: (2018)

Discordance in investigator-reported and adjudicated sudden death in TIOSPIR
por: Wise, Robert A., et al.
Publicado: (2017)

The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials
por: Eriksson, Göran, et al.
Publicado: (2017)

Meeting the GOLD Standard: COPD Treatment in the UK Today
por: Calverley, P.M.A.
Publicado: (2019)

Factors associated with change in exacerbation frequency in COPD
por: Donaldson, Gavin C, et al.
Publicado: (2013)

A score to predict short-term risk of COPD exacerbations (SCOPEX)
por: Make, Barry J, et al.
Publicado: (2015)

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
por: Calverley, Peter M, et al.
Publicado: (2016)

Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations
por: Calverley, Peter M, et al.
Publicado: (2016)

The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients
por: Song, Qing, et al.
Publicado: (2021)

Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes
por: Anzueto, A, et al.
Publicado: (2009)

Optimizing bronchodilation in the prevention of COPD exacerbations
por: Miravitlles, Marc, et al.
Publicado: (2017)

Integrating COPD care in Italy
por: Calverley, Peter MA
Publicado: (2014)

Time To Revise COPD Treatment Algorithm
por: Matsunaga, Kazuto, et al.
Publicado: (2019)

COPD in the time of COVID-19
por: Calverley, Peter M.A.
Publicado: (2021)

Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT(®) studies
por: Miravitlles, Marc, et al.
Publicado: (2009)

The need to further understand who gets hospitalized for a COPD exacerbation
por: Maselli, Diego J, et al.
Publicado: (2012)

ACO (Asthma–COPD Overlap) Is Independent from COPD: The Case Against
por: Calverley, Peter M. A., et al.
Publicado: (2021)

GOLD 2023 Executive Summary: responses from the GOLD Scientific Committee
por: Agustí, Alvar, et al.
Publicado: (2023)

A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology
por: Wilson, Robert, et al.
Publicado: (2011)

Prevalence of different comorbidities in COPD patients by gender and GOLD stage
por: Dal Negro, R. W., et al.
Publicado: (2015)

Variation in Assignment of the COPD Patients into a GOLD Group According to Symptoms Severity
por: Moya-Álvarez, Virginia, et al.
Publicado: (2020)

Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial
por: Celli, Bartolome R, et al.
Publicado: (2019)

Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial
por: Brigham, Emily P., et al.
Publicado: (2021)

Geographic differences in clinical characteristics and management of COPD: the EPOCA study
por: Miravitlles, Marc, et al.
Publicado: (2008)

Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
por: Rennard, Stephen I, et al.
Publicado: (2011)

Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England
por: Sansbury, Leah B, et al.
Publicado: (2021)

Community-Acquired Respiratory Complications in the Intensive Care Unit: Pneumonia and Acute Exacerbations of COPD
por: Restrepo, M. I., et al.
Publicado: (2010)

Roflumilast: a review of its use in the treatment of COPD
por: Wedzicha, Jadwiga A, et al.
Publicado: (2016)

From GOLD 0 to Pre-COPD
por: Han, MeiLan K., et al.
Publicado: (2021)

Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry
por: Kobayashi, Seiichi, et al.
Publicado: (2018)

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial
por: Tashkin, Donald P., et al.
Publicado: (2018)

Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort – Determinants and Consequences
por: Lutter, Johanna I, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vu67l6j6n1e2t67opdbn1g32ot